Previous 10 | Next 10 |
On track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI ac...
SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy. SER-401 did not show efficacy in metastatic melanoma patients. SER-155 has not yet achieved proof of concept but is the most promi...
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel clas...
The following slide deck was published by Finch Therapeutics Group, Inc. in conjunction with this event. For further details see: Finch Therapeutics (FNCH) Investor Presentation - Slideshow
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel c...
Finch Therapeutics press release (NASDAQ:FNCH): Q1 GAAP EPS of -$0.52. Revenue of $0.35M. Susan Graf appointed board chair and Howard Franklin chief medical officer. Shares +3.59%. For further details see: Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M
FDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update call to...
Seth Klarman’s 13F portfolio value decreased from $10.13B to $9.30B this quarter. Baupost Group increased Fiserv, Dropbox, Encompass Health, Nuvation Bio, and ironSource while reducing Joby Aviation and dropping Pershing Square Tontine and NortonLifeLock. The portfolio cont...
Gainers: Better Therapeutics (BTTX) +34%. Great Elm (GEG) +9%. Nuvectis Pharma (NVCT) +8%. Viatris (VTRS) +5%. BioNTech (BNTX) +3%. Losers: TherapeuticsMD (TXMD) -30%. Sutro Biopharma (STRO) -12%. NanoViricides (NNVC) -12%. RedHill Biopharma (RDHL)...
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel c...
News, Short Squeeze, Breakout and More Instantly...
Finch Therapeutics Group Inc. Company Name:
FNCH Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 8.6% to $0.0384 on volume of 89,961,220 shares Nuburu Inc. (BURU) rose 29.4% to $0.207 on volume of 85,213,370 shares Novo Integrated Sciences Inc. (NVOS) rose 139.5% to $1.08 on volume ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...